SAVARA ANNOUNCES ENCORE PRESENTATIONS OF RESULTS FROM THE PHASE 3 CLINICAL TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) CONGRESS 2026

Reuters · 15h ago

Please log in to view news